pharmaphorum December 5, 2023
Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.
The eight-week study tested ALTO-300, a once-daily oral drug with an undisclosed mechanism of action, in 239 patients with major depressive disorder (MDD) that was not responding well to their current treatment.
It included a subgroup of 110 patients who were selected for inclusion based on an artificial intelligence-powered assessment of an electroencephalogram (EEG) at baseline, which indicated they had a ‘brain biomarker’ that, according to Alto, made them likely to respond to treatment with ALTO-300.
The drug was added to their standard treatment and, after four weeks, significantly more patients with the EEG...
Today's Sponsors
Today's Sponsor